Three’s A Crowd: Cimzia Joins Humira, Remicade For Crohn’s Disease
Executive Summary
UCB is pushing pricing and other incentives for Cimzia (certolizumab) - rather than clinical benefit - to break into a crowded Crohn's disease market that already includes two well-established tumor necrosis factor inhibitors
You may also be interested in...
Market Snapshot: Anti-TNFs Grow Despite Tough Market
At least one class of therapies - anti-tumor necrosis factors - is booming, even in the midst of one of the worst years financially for the pharmaceutical industry
Market Snapshot: Anti-TNFs Grow Despite Tough Market
At least one class of therapies - anti-tumor necrosis factors - is booming, even in the midst of one of the worst years financially for the pharmaceutical industry
TNF Blockers Not Seen To Boost Cancer Risk In RA Patients Tracked In Large Spanish Registry
The only elevated cancer type in patients taking the biologic drugs was non-melanoma skin cancer, investigator reports at rheumatology scientific conference.